João Arezes

João Arezes

Auto-generated profile, based on publicly available information

João Arezes

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in Blood
Verified
Journal Article
Open access
PDF file
JAJoão Arezes
João Arezes
NFNiall Foy
Niall Foy
KMKirsty McHugh
Kirsty McHugh
ASAnagha Sawant
Anagha Sawant
DQDoris Quinkert
Doris Quinkert
ADAlexander Drakesmith
Alexander Drakesmith
Key Points: ERFE suppresses BMP/SMAD signaling in vitro and in vivo. ERFE inhibits hepcidin induction by BMP5, BMP6, and BMP7.

1 January 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
JAJoão Arezes
João Arezes
GJGrace Jung
Grace Jung
VGVictoria Gabayan
Victoria Gabayan
EVErika Valore
Erika Valore
PRPiotr Ruchala
Piotr Ruchala
YBYonca Bulut
Yonca Bulut

20 July 2017 in Blood
Verified
Journal Article
Open access
PDF file
DSDeborah Stefanova
Deborah Stefanova
ARAntoan Raychev
Antoan Raychev
JAJoao Arezes
Joao Arezes
PRPiotr Ruchala
Piotr Ruchala
VGVictoria Gabayan
Victoria Gabayan
ENElla Nemeth
Ella Nemeth
Key Points: In mouse models, hepcidin participates in innate immunity by controlling NTBI. NTBI-dependent infections can be treated with hepcidin agonists in mouse models of hereditary hemochromatosis or parenteral iron overload.

13 May 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
PLPei Jin Lim
Pei Jin Lim
TDTiago L Duarte
Tiago L Duarte
JAJoão Arezes
João Arezes
DGDaniel Garcia-Santos
Daniel Garcia-Santos
AHAmel Hamdi
Amel Hamdi
ADAlexander Drakesmith
Alexander Drakesmith

14 May 2015 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
JAJ. Arezes
J. Arezes
ENElla Nemeth
Ella Nemeth
Summary: Hepatic hormone hepcidin is a principal regulator of iron homeostasis and a pathogenic factor in common iron disorders. Hepcidin deficiency causes iron overload in hereditary hemochromatosis and iron‐loading anemias, whereas hepcidin excess causes or contributes to the development of iron‐restricted anemia in inflammatory diseases, infections, some cancers, and chronic kidney disease. Because of this, hepcidin may become a useful tool for diagnosis and management of iron disorders. Furthermore, a number of strategies that target hepcidin, its receptor, and its regulators are under development as novel therapeutic approaches for diseases associated with iron dysregulation.

20 February 2020 in Blood
Verified
Journal Article
Open access
PDF file
JAJoão Arezes
João Arezes
NFNiall Foy
Niall Foy
KMKirsty McHugh
Kirsty McHugh
DQDoris Quinkert
Doris Quinkert
SBSusan Benard
Susan Benard
ADAlexander Drakesmith
Alexander Drakesmith
Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6. Hepcidin suppression allows for the mobilization of iron to the bone marrow for the production of red blood cells. Aberrantly high circulating ERFE in conditions of stress erythropoiesis, such as in patients with β-thalassemia, promotes the tissue iron accumulation that substantially contributes to morbidity in these patients. Here we developed antibodies against ERFE to prevent hepcidin suppression and to correct the iron loading phenotype in a mouse model of β-thalassemia [Hbb(th3/+) mice] and used these antibodies as tools to further characterize ERFE’s mechanism of action. We show that ERFE binds to BMP6 with nanomolar affinity and binds BMP2 and BMP4 with somewhat weaker affinities. We found that BMP6 binds the N-terminal domain of ERFE, and a polypeptide derived from the N terminus of ERFE was sufficient to cause hepcidin suppression in Huh7 hepatoma cells and in wild-type mice. Anti-ERFE antibodies targeting the N-terminal domain prevented hepcidin suppression in ERFE-treated Huh7 cells and in EPO-treated mice. Finally, we observed a decrease in splenomegaly and serum and liver iron in anti–ERFE-treated Hbb(th3/+) mice, accompanied by an increase in red blood cells and hemoglobin and a decrease in reticulocyte counts. In summary, we show that ERFE binds BMP6 directly and with high affinity, and that antibodies targeting the N-terminal domain of ERFE that prevent ERFE–BMP6 interactions constitute a potential therapeutic tool for iron loading anemias.